Download App

Log in to access Online Inquiry
Company Overview More
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
CEO: Dobak M.D., John D.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > DMTK DermTech > Detailed Quotes

DMTK DermTech

6.230-0.470-7.01%
Close 05/23 19:10 ET
6.310+0.08+1.28%
Post Mkt Price 05/23 18:03 ET
High
6.840
Open
6.840
Turnover
4.79M
Low
6.120
Pre Close
6.700
Volume
761.75K
Market Cap
186.53M
P/E(TTM)
Loss
52wk High
48.320
Shares
29.94M
P/E(Static)
Loss
52wk Low
6.120
Float Cap
141.89M
Bid/Ask %
0.00%
Historical High
84.490
Shs Float
22.78M
Volume Ratio
0.97
Historical Low
4.520
Dividend TTM
--
Div Yield TTM
--
P/B
0.92
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
3.35%
Amplitude
10.75%
Avg Price
6.286
Lot Size
1
Float Cap
141.89M
Bid/Ask %
0.00%
Historical High
84.490
Shs Float
22.78M
Volume Ratio
0.97
Historical Low
4.520
Dividend TTM
--
P/B
0.92
Dividend LFY
--
Turnover Ratio
3.35%
Amplitude
10.75%
Avg Price
6.286
Lot Size
1
Price Forecast

No Data

News

Comment